McKnight's Long-Term Care News2h
A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
Pharmabiz9h
AbbVie’s Vyalev receives US FDA approval to treat adults living with advanced Parkinson's disease
AbbVie announced that the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the ...
emjreviews.com13h
24-Hour Therapy for Parkinson’s: The First Of Its Kind
The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.
WebMD1d
FDA Approves New Treatment for Advanced Parkinson’s Disease
The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).
Pharmaceutical Technology1d
Avadel wins FDA approval for narcolepsy drug Lumryz in children
The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s ...
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...
Medscape1d
FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s
Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease.
The Pharma Letter1d
FDA finally approves Vyalev for Parkinson’s disease
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and ...
AbbVie’s Vyalev approved by FDA in advanced Parkinson’s disease
AbbVie announced that the FDA has approved Vyalev as the first and only subcutaneous 24-hour infusion of levodopa-based ...
pharmaphorum1d
AbbVie gets continuous Parkinson's drug over the line in US
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...
Pharmaceutical Technology1d
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
The US FDA has approved AbbVie's VYALEV to treat motor fluctuations in adults with advanced Parkinson's disease (PD).
Science Daily1d
HIV and AIDS News
Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...